Success Metrics

Clinical Success Rate
50.0%

Based on 2 completed trials

Completion Rate
50%(2/4)
Active Trials
4(36%)
Results Posted
100%(2 trials)
Terminated
2(18%)

Phase Distribution

Ph phase_1
2
18%
Ph phase_2
5
45%
Ph phase_3
3
27%
Ph phase_4
1
9%

Phase Distribution

2

Early Stage

5

Mid Stage

4

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
2(18.2%)
Phase 2Efficacy & side effects
5(45.5%)
Phase 3Large-scale testing
3(27.3%)
Phase 4Post-market surveillance
1(9.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

40.0%

2 of 5 finished

Non-Completion Rate

60.0%

3 ended early

Currently Active

4

trials recruiting

Total Trials

11

all time

Status Distribution
Active(6)
Completed(2)
Terminated(3)

Detailed Status

Recruiting4
Completed2
Terminated2
Not yet recruiting1
Withdrawn1
Enrolling by invitation1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
4
Success Rate
50.0%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (18.2%)
Phase 25 (45.5%)
Phase 33 (27.3%)
Phase 41 (9.1%)

Trials by Status

completed218%
not_yet_recruiting19%
withdrawn19%
enrolling_by_invitation19%
recruiting436%
terminated218%

Recent Activity

4 active trials
Showing 5 of 11
recruitingphase_3

Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis

NCT06022939
recruitingphase_3

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

NCT04566328
completedphase_2

Daratumumab in STK11 Mutated NSCLC

NCT05807048
not_yet_recruitingphase_2

ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma

NCT07247097
completedphase_4

Home Based Daratumumab Administration for Patients With Multiple Myeloma

NCT05511428
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT06022939Phase 3

Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis

Recruiting
NCT04566328Phase 3

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

Recruiting
NCT05807048Phase 2

Daratumumab in STK11 Mutated NSCLC

Completed
NCT07247097Phase 2

ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma

Not Yet Recruiting
NCT05511428Phase 4

Home Based Daratumumab Administration for Patients With Multiple Myeloma

Completed
NCT07110844Phase 2

Teclistamab-Daratumumab in AL Amyloidosis

Recruiting
NCT05300451Phase 2

Daratumumab in HLA Desensitization Prior to Transplantation

Enrolling By Invitation
NCT06046287Phase 2

Daratumumab for Polyneuropathy Associated With MGUS

Withdrawn
NCT05561387Phase 3

Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

Recruiting
NCT04776018Phase 1

A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM)

Terminated
NCT04956302Phase 1

Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma

Terminated

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11